ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

INKT MiNK Therapeutics Inc

0.9407
0.00 (0.00%)
Pre Market
Last Updated: 18:16:47
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
MiNK Therapeutics Inc INKT NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 0.9407 18:16:47
Open Price Low Price High Price Close Price Previous Close
0.9407
more quote information »

Recent News

Date Time Source Heading
30/4/202421:30GLOBEMiNK to Provide Corporate Update and First Quarter 2024..
09/4/202402:00GLOBEMiNK Therapeutics Announces Promising Preclinical Activity..
21/3/202422:26IHMARKETNEWSU.S. Index Futures Rise as Fed’s Dovish Outlook Spurs..
21/3/202422:00GLOBEMiNK Reports Fourth Quarter and Year-End 2023 Results
07/3/202423:30GLOBEMiNK to Provide Corporate Update and Fourth Quarter & Full..
06/3/202410:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202408:05EDGAR2Form 8-K - Current report
15/2/202400:00EDGAR2Form 8-K - Current report
15/2/202400:00GLOBEFirst Refractory Gastric Cancer Patient Dosed in Phase 2..
07/2/202400:00GLOBEMiNK Therapeutics' AgenT-797 Shows Promising Results in the..
31/1/202400:00GLOBEMiNK’s AgenT-797 Offers New Hope in Overcoming ICI..
19/1/202412:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202323:30GLOBEImmunoScape and MiNK Therapeutics Collaborate to Accelerate..
06/12/202310:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/11/202323:00EDGAR2Form 8-K - Current report
09/11/202323:00GLOBEMiNK Therapeutics Reports Third Quarter 2023 Results
04/11/202303:00GLOBEMiNK Therapeutics Presents Clinical Activity and Long-Term..
30/10/202323:00GLOBEMiNK to Provide Third Quarter 2023 Financial Report and..
18/10/202307:15EDGAR2Form 8-K - Current report
27/9/202323:05GLOBEMiNK Therapeutics To Present Data Update From Allogeneic..
07/9/202307:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/9/202307:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/8/202322:30GLOBEMiNK Therapeutics to Participate in September Investor..
11/8/202321:44EDGAR2Form S-8 - Securities to be offered to employees in employee..
10/8/202321:30EDGAR2Form 8-K - Current report
10/8/202321:30GLOBEMiNK Therapeutics Reports Second Quarter 2023 Results
10/8/202321:26EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
28/7/202322:30GLOBEMiNK to Provide Second Quarter 2023 Financial Report and..
05/6/202321:30GLOBEMiNK Therapeutics Announces Virtual Annual Shareholders..
22/5/202322:30GLOBEMiNK Presents Clinical Data on Allogeneic iNKT Cells..
18/5/202322:30GLOBEMiNK's Novel FAP-CAR-iNKT Presented at ASGCT
11/5/202322:00GLOBEMiNK Therapeutics Reports Corporate Update and First Quarter..

Your Recent History

Delayed Upgrade Clock